Pyoderma gangrenosum (PG) is a complex disease with limited therapeutic options. Here we report the use of higher dose of guselkumab, a monoclonal antibody targeting interleukin (IL‐) 23, in the treatment of PG in a medically complex patient. This case contributes additional evidence supporting the potential effectiveness of guselkumab in the treatment of PG and highlights the necessity for larger studies to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Sarsam et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: